
ABBOTT

TriClip™
Transcatheter Edge-to-Edge Repair



Impact of center experience on 30-day outcomes after T-TEER with the TriClip™ system

Findings from the STS/ACC TVT registry


TriClip™ TEER demonstrates consistent safety and efficacy outcomes across sites with varying procedural volume, while procedure times decreased with increasing case volume.

STS/ACC TVT registry

3035
patients treated with TriClip™ TEER system

278
sites in the United States

Procedure time decreases with increased experience



For U.S. audience, see Important Safety Information referenced within. For audiences outside of the U.S., always check the regulatory status of the device in your region.

Consistent 30-day outcomes across center volume

30-day outcomes	Sites with <10 patients (649 patients)	Sites with ≥10 patients (2386 patients)
All-cause mortality	1.7%	1.3%
Heart failure hospitalization	3.2%	2.1%
Single leaflet device attachment	1.7%	1.4%
Major bleeding	1.1%	0.8%
New permanent pacemaker	0.5%	0.5%
Stroke	0.3%	0.3%
Moderate or less TR	86%	87%
KCCQ-OS score improvement (points)	25	21
NYHA Class I/II	78%	79%

B. Whisenant, Impact of Center Experience on 30-Day outcomes following T-TEER with the TriClip System - Findings from the STS/ACC TVT Registry. Data presented at TCT 2026.

For U.S. Audiences Only
Rx Only
Important Safety Information
TRICLIP™ G5 SYSTEM

Indications
The TriClip™ G5 System is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.

Contraindications
The TriClip™ G5 System is contraindicated for use in patients with the following conditions: Intolerance, including allergy or untreatable hypersensitivity, to procedural anticoagulation; Untreatable hypersensitivity to Implant components (nickel-titanium alloy, cobalt-chromium alloy); Active endocarditis or other active infection of the tricuspid valve.

Potential Adverse Events
The following events have been identified as possible complications of the TriClip™ G5 Procedure. Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials and drug reactions to anticoagulation, or antiplatelet drugs; Additional treatment / surgery from device-related complications; Bleeding; Blood disorders (including coagulopathy, hemolysis, and Heparin Induced Thrombocytopenia (HIT)); Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias); Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, unstable angina, and stable angina); Cardiac perforation; Cardiac tamponade; Chest pain; Death; Dyspnea; Edema; Embolization (device or components of the device); Endocarditis; Fever or hyperthermia; Fluoroscopy and Transesophageal echocardiogram (TEE) -related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation, Esophageal perforation, Gastrointestinal bleeding; Hypotension / hypertension; Infection including: Septicemia; Nausea or vomiting; Pain; Pericardial effusion; Stroke / cerebrovascular accident (CVA) and transient ischemic attack (TIA); System organ failure: Cardio-respiratory arrest, Worsening heart failure, Pulmonary congestion, Respiratory dysfunction or failure or atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic); Thrombosis; Tricuspid valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement / rupture, Single leaflet device attachment (SLDA), Dislodgement of previously implanted devices, Tissue damage, Tricuspid valve stenosis, Worsening, persistent or residual regurgitation; Vascular access complications which may require additional intervention, including: Wound dehiscence, Bleeding of the access site, Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation (rupture), vascular occlusion, Embolism (air, thrombus), Peripheral nerve injury; Venous thrombosis (including deep vein thrombosis) and thromboembolism (including pulmonary embolism).

For U.S. audience, see Important Safety Information referenced within. For audiences outside of the U.S., always check the regulatory status of the device in your region.

CAUTION: Product(s) intended for use by or under the direction of a physician. Prior to use, reference to the Instructions for Use inside the product carton (when available), or at www.eifu.abbott for more detailed information on Indications, Contraindications, Warnings, Precautions, and Adverse Events. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photo(s) on file at Abbott.

Abbott
3200 Lakeside Dr., Santa Clara, CA 95054 USA
™ Indicates a trademark of the Abbott group of companies.
www.structuralheart.abbott
©2026 Abbott. All rights reserved. MAT-2682119 v1.0 | Item approved for Global use.